Search Results - E.P. Nacharova

  • Showing 1 - 12 results of 12
Refine Results
  1. 1
    Difficulties in Differential Diagnosis of Post-Vaccination Period. Practical Examples

    Difficulties in Differential Diagnosis of Post-Vaccination Period. Practical Examples by E. P. Nacharova, S. M. Kharit

    Published 2017-12-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Convulsive syndrome in the post-vaccination period: is there a connection with the vaccine?

    Convulsive syndrome in the post-vaccination period: is there a connection with the vaccine? by E. P. Nacharova, S. M. Kharit, A. A. Ruleva

    Published 2021-01-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    SAFETY OF INACTIVATED POLYMER-SUBUNIT THREE VALENCE INFLUENZA VACCINE. POSTREGISTRATIONAL OBSERVATION

    SAFETY OF INACTIVATED POLYMER-SUBUNIT THREE VALENCE INFLUENZA VACCINE. POSTREGISTRATIONAL OBSERVATION by S.M. Kharit, E.P. Nacharova, T.V. Chernyaeva

    Published 2009-07-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN

    EFFICIENCY AND SAFETY OF USING PIDOTIMOD IN VACCINATED RISK GROUP CHILDREN by A. A. Ruleva, S. M. Kharit, E. P. Nacharova, I. V. Fridman

    Published 2013-01-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    VACCINATION OF CHILDREN AGAINST MEASLES, PAROTIDITIS AND VITAMINOTHERAPY

    VACCINATION OF CHILDREN AGAINST MEASLES, PAROTIDITIS AND VITAMINOTHERAPY by S.M. Kharit, T.V. Chernyaeva, E.P. Nacharova, O.V. Goleva

    Published 2007-12-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    The estimation of safety booster vaccination children is more senior than 1,5 years against diphtheria, perussis, tetanus, poliomyelitis and Haemophilus influenzae type B with Pentaxim

    The estimation of safety booster vaccination children is more senior than 1,5 years against diphtheria, perussis, tetanus, poliomyelitis and Haemophilus influenzae type B with Pent... by S. M. Harit, T. V. Tchernyaeva, E. P. Nacharova, G. A. Vasileva, A. A. Ruleva

    Published 2014-09-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    POTENTIAL OF THE RUSSIAN FEDERATION IN EXPORTS OF ANTI-INFLUENZA VACCINES IN LATIN AMERICAN COUNTRIES

    POTENTIAL OF THE RUSSIAN FEDERATION IN EXPORTS OF ANTI-INFLUENZA VACCINES IN LATIN AMERICAN COUNTRIES by V. P. Trukhin, I. A. Narkevich, E. P. Nacharova, S. V. Uiba, I. I. Basakina

    Published 2019-01-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Pertussis vaccination: problems, possible solutions

    Pertussis vaccination: problems, possible solutions by S. M. Kharit, O. V. Iosefovich, I. V. Fridman, E. P. Nacharova, K. K. Tikhomirova

    Published 2020-06-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    RE-VACCINATION OF CHILDREN OVER 1,5 YEARS OLD AGAINST DIPHTHERIA, PERTUSSIS, TETANUS, POLIOMYELITIS AND HEMOPHILIC INFECTION

    RE-VACCINATION OF CHILDREN OVER 1,5 YEARS OLD AGAINST DIPHTHERIA, PERTUSSIS, TETANUS, POLIOMYELITIS AND HEMOPHILIC INFECTION by S.M. Kharit, T.V. Chernyaeva, E.P. Nacharova, G.A. Vasil’eva, A.A. Ruleva

    Published 2009-11-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    Improving the Monitoring of Adverse Events Following Immunization (in Order of Discussion)

    Improving the Monitoring of Adverse Events Following Immunization (in Order of Discussion) by N. I. Briko, L. S. Namazova-Baranova, Y. V. Lobzin, S. M. Kharit, E. P. Nacharova, I. V. Feldblium

    Published 2016-12-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    IMMUNIZATION AGAINST MEASLES AND DIPHTHERIA IN CHILDREN WITH HIV

    IMMUNIZATION AGAINST MEASLES AND DIPHTHERIA IN CHILDREN WITH HIV by S.M. Kharit, L.M. Lianko, O.V. Goleva, A.S. Kvetnaya, S.V. Petlenko, E.P. Nacharova, N.F. Snegova

    Published 2006-03-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years

    The results of an Open, Randomized Comparative Clinical Study to Assess the Reactogenicity, Safety and Immunogenicity of the Vaccine EntseVir in Children Aged 3 to 17 Years by S. M. Kharit, A. A. Ruleva, I. V. Fridman, E. P. Nacharova, L. A. Alekseeva, G. A. Vasil'eva, A. A. Vilnic, M. V. Ivanova

    Published 2015-04-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: